Karyopharm Therapeutics’ (KPTI) Outperform Rating Reaffirmed at Royal Bank of Canada

Karyopharm Therapeutics (NASDAQ:KPTI)‘s stock had its “outperform” rating reiterated by analysts at Royal Bank of Canada in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $3.00 target price on the stock. Royal Bank of Canada’s price objective indicates a potential upside of 274.95% from the stock’s previous close.

Several other brokerages have also recently issued reports on KPTI. HC Wainwright decreased their price objective on Karyopharm Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, June 28th. Robert W. Baird decreased their price objective on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating on the stock in a report on Wednesday. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $4.67.

Karyopharm Therapeutics Stock Down 4.7 %

KPTI stock traded down $0.04 during midday trading on Wednesday, hitting $0.80. The company’s stock had a trading volume of 478,873 shares, compared to its average volume of 1,499,691. Karyopharm Therapeutics has a 12 month low of $0.62 and a 12 month high of $1.95. The firm has a market capitalization of $99.71 million, a price-to-earnings ratio of -0.63 and a beta of 0.21. The company has a 50 day moving average of $0.94 and a two-hundred day moving average of $1.12.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.01. The business had revenue of $33.13 million during the quarter, compared to the consensus estimate of $35.02 million. On average, analysts anticipate that Karyopharm Therapeutics will post -1.16 earnings per share for the current fiscal year.

Insider Activity at Karyopharm Therapeutics

In related news, Director Deepika Pakianathan sold 360,744 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $1.00, for a total transaction of $360,744.00. Following the sale, the director now owns 11,209 shares in the company, valued at approximately $11,209. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders have sold 1,275,473 shares of company stock worth $1,234,542. Company insiders own 4.30% of the company’s stock.

Institutional Trading of Karyopharm Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets increased its stake in Karyopharm Therapeutics by 6.5% in the fourth quarter. BNP Paribas Financial Markets now owns 1,769,184 shares of the company’s stock worth $1,530,000 after purchasing an additional 108,286 shares during the period. Ikarian Capital LLC increased its stake in Karyopharm Therapeutics by 2.3% in the first quarter. Ikarian Capital LLC now owns 409,355 shares of the company’s stock worth $618,000 after purchasing an additional 9,355 shares during the period. Los Angeles Capital Management LLC purchased a new stake in Karyopharm Therapeutics in the fourth quarter worth $339,000. Panagora Asset Management Inc. purchased a new stake in Karyopharm Therapeutics in the fourth quarter worth $197,000. Finally, Acadian Asset Management LLC purchased a new stake in Karyopharm Therapeutics in the second quarter worth $167,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).